DApagliflozin 10 mg and VildagliptiN 100 mg SR use in Cardiology Practice A real world Clinical Insight (DAa-ViNCI Study)

Le résumé fourni par la source

Background: Diabetes mellitus is a global epidemic characterized by persistently high blood sugar levels. The combination of dipeptidyl peptidase-4 inhibitors (DPP-4i) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) is potentially effective in managing type 2 diabetes mellitus (T2DM). The present study analyzed the efficacy, safety, and practice patterns of the fixed-dose (FDC) of vildagliptin 100 mg and dapagliflozin 10 mg in cardiology practice. Methods: This retrospective, non-randomized, non-comparative, multi-center study was conducted at 200 sites across India from June 2023 to March 2024. Patients of either sex, >18 years of age, diagnosed with T2DM, and who received the FDC of vildagliptin 100 mg SR and dapagliflozin 10 mg for the treatment of their condition were included. Comprehensive patient information collected from the medical records were analyzed. Results: A total of 2,199 patients were included, with a mean age of 55.04 years. Approximately 63% of the patients were male. Hypertension (74.81%) was the most common comorbidity, followed by dyslipidemia (38.52%). The FDC of vildagliptin 100 mg SR and dapagliflozin 10 mg reduced the mean glycated hemoglobin (7.7% vs 5.8%), fasting plasma glucose (142.4 mg/dL vs 90.2 mg/dL), postprandial glucose (205.64 mg/dL vs 123.38 mg/dL) levels from baseline to 3 months. The mean systolic blood pressure decreased from 141.35 mmHg to 131.59 mmHg, and the mean diastolic blood pressure decreased from 89.65 mmHg to 84.42 mmHg following FDC therapy. Glycemic goals were achieved in 78.08% of patients. Adverse events were reported in 0.36% of patients. Conclusion: The FDC of vildagliptin and dapagliflozin demonstrated substantial efficacy in managing T2DM and was well-tolerated, with a low incidence of adverse events.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.